Literature DB >> 21300764

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.

Byron C Burnette1, Hua Liang, Youjin Lee, Lukasz Chlewicki, Nikolai N Khodarev, Ralph R Weichselbaum, Yang-Xin Fu, Sogyong L Auh.   

Abstract

The most widely held explanation for the efficacy of local radiotherapy (RT) is based on direct cytotoxicity to cancer cells through the induction of lethal DNA damage. Recent studies have shown that local ablative radiation of established tumors can lead to increased T-cell priming and T-cell-dependent tumor regression, but the underlying mechanism remains unclear. Here, we describe an essential role for type I IFN in local RT-mediated tumor control. We show that ablative RT increases intratumoral production of IFN-β and, more surprisingly, the antitumor effect of RT is abolished in type I IFN nonresponsive hosts. Furthermore, the major target of RT-induced type I IFN is the hematopoietic compartment. RT drastically enhances the cross-priming capacity of tumor-infiltrating dendritic cells (TIDC) from wild-type mice but not type I IFN receptor-deficient mice. The enhanced cross-priming ability of TIDCs after RT was dependent on autocrine production of type I IFNs. By using adenoviral-mediated expression of IFN-β, we show that delivery of exogenous IFN-β into the tumor tissue in the absence of RT is also sufficient to selectively expand antigen-specific T cells leading to complete tumor regression. Our study reveals that local high-dose RT can trigger production of type I IFN that initiates a cascading innate and adaptive immune attack on the tumor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300764      PMCID: PMC3070872          DOI: 10.1158/0008-5472.CAN-10-2820

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Complex modulation of cell type-specific signaling in response to type I interferons.

Authors:  Anette H H van Boxel-Dezaire; M R Sandhya Rani; George R Stark
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 2.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

3.  Programming for CD8 T cell memory development requires IL-12 or type I IFN.

Authors:  Zhengguo Xiao; Kerry A Casey; Stephen C Jameson; Julie M Curtsinger; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

4.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Authors:  Lyse A Norian; Paulo C Rodriguez; Leigh A O'Mara; Jovanny Zabaleta; Augusto C Ochoa; Marina Cella; Paul M Allen
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

5.  IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity.

Authors:  Andrew G Sikora; Nina Jaffarzad; Yared Hailemichael; Alexander Gelbard; Spencer W Stonier; Kimberly S Schluns; Loredana Frasca; Yanyan Lou; Chengwen Liu; Helen A Andersson; Patrick Hwu; Willem W Overwijk
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

6.  Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Authors:  Eduardo Huarte; Juan R Cubillos-Ruiz; Yolanda C Nesbeth; Uciane K Scarlett; Diana G Martinez; Ronald J Buckanovich; Fabian Benencia; Radu V Stan; Tibor Keler; Pablo Sarobe; Charles L Sentman; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2008-09-03       Impact factor: 12.701

7.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

8.  Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.

Authors:  Ping Yu; Youjin Lee; Yang Wang; Xiaojuan Liu; Sogyong Auh; Thomas F Gajewski; Hans Schreiber; Zhaoyang You; Campbell Kaynor; Xinzhong Wang; Yang-Xin Fu
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

9.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer.

Authors:  Ralph R Weichselbaum; Hemant Ishwaran; Taewon Yoon; Dimitry S A Nuyten; Samuel W Baker; Nikolai Khodarev; Andy W Su; Arif Y Shaikh; Paul Roach; Bas Kreike; Bernard Roizman; Jonas Bergh; Yudi Pawitan; Marc J van de Vijver; Andy J Minn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-10       Impact factor: 11.205

10.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

View more
  309 in total

Review 1.  Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.

Authors:  Leticia Corrales; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2015-09-15       Impact factor: 12.531

Review 2.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.

Authors:  Anish Prasanna; Mansoor M Ahmed; Mohammed Mohiuddin; C Norman Coleman
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

3.  Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.

Authors:  Leticia Corrales; Thomas F Gajewski
Journal:  Cytokine       Date:  2015-08-24       Impact factor: 3.861

4.  A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.

Authors:  Jonathan D Schoenfeld; Danielle N Margalit; Julie L Kasperzyk; Irene M Shui; Jennifer R Rider; Mara M Epstein; Allison Meisner; Stacey A Kenfield; Neil E Martin; Paul L Nguyen; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

5.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 6.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

7.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

Authors:  Xuanming Yang; Xunmin Zhang; May Lynne Fu; Ralph R Weichselbaum; Thomas F Gajewski; Yajun Guo; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

Review 8.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

9.  Effects of retinoic acid-inducible gene-I-like receptors activations and ionizing radiation cotreatment on cytotoxicity against human non-small cell lung cancer in vitro.

Authors:  Hironori Yoshino; Miyu Iwabuchi; Yuka Kazama; Maho Furukawa; Ikuo Kashiwakura
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

Review 10.  Radiation and inflammation.

Authors:  Dörthe Schaue; Ewa D Micewicz; Josephine A Ratikan; Michael W Xie; Genhong Cheng; William H McBride
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.